Alliancebernstein L.P. Has $1.03 Million Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Alliancebernstein L.P. trimmed its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 64.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 36,010 shares of the specialty pharmaceutical company's stock after selling 66,120 shares during the period. Alliancebernstein L.P. owned about 0.11% of Collegium Pharmaceutical worth $1,032,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. JPMorgan Chase & Co. increased its stake in shares of Collegium Pharmaceutical by 173.6% in the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company's stock worth $10,711,000 after buying an additional 175,892 shares during the last quarter. Barclays PLC grew its position in Collegium Pharmaceutical by 152.2% during the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company's stock worth $2,899,000 after purchasing an additional 45,291 shares in the last quarter. Sanctuary Advisors LLC grew its position in Collegium Pharmaceutical by 10.7% during the 3rd quarter. Sanctuary Advisors LLC now owns 17,976 shares of the specialty pharmaceutical company's stock worth $695,000 after purchasing an additional 1,731 shares in the last quarter. Principal Financial Group Inc. grew its position in Collegium Pharmaceutical by 3.9% during the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company's stock worth $67,459,000 after purchasing an additional 64,958 shares in the last quarter. Finally, Franklin Resources Inc. grew its position in Collegium Pharmaceutical by 13.4% during the 3rd quarter. Franklin Resources Inc. now owns 30,625 shares of the specialty pharmaceutical company's stock worth $1,164,000 after purchasing an additional 3,620 shares in the last quarter.

Wall Street Analyst Weigh In

COLL has been the topic of several research analyst reports. Piper Sandler lowered their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 4th. HC Wainwright reiterated a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Needham & Company LLC reissued a "buy" rating and set a $46.00 target price on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. Finally, StockNews.com lowered shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, April 19th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $43.60.

Collegium Pharmaceutical Price Performance

Shares of Collegium Pharmaceutical stock traded up $0.50 during midday trading on Thursday, hitting $26.49. 34,647 shares of the company were exchanged, compared to its average volume of 414,768. The firm has a 50 day simple moving average of $28.51 and a 200-day simple moving average of $30.96. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. Collegium Pharmaceutical, Inc. has a 52 week low of $23.23 and a 52 week high of $42.29. The firm has a market cap of $851.02 million, a P/E ratio of 11.41 and a beta of 0.76.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping analysts' consensus estimates of $1.54 by $0.09. The firm had revenue of $181.95 million during the quarter, compared to analysts' expectations of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. Research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Insider Buying and Selling at Collegium Pharmaceutical

In related news, EVP Scott Dreyer sold 2,255 shares of the business's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $67,650.00. Following the transaction, the executive vice president now owns 124,421 shares in the company, valued at $3,732,630. The trade was a 1.78 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the business's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the completion of the transaction, the executive vice president now owns 154,204 shares in the company, valued at approximately $4,330,048.32. The trade was a 20.60 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 81,693 shares of company stock worth $2,334,994 over the last quarter. Corporate insiders own 2.51% of the company's stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.